Compare ConocoPhillips (COP) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Citius Pharmaceuticals Inc — how do they compare? ConocoPhillips trades at $133.5 (market cap $155.98B), while Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M). The key difference: ConocoPhillips is far larger — about 11311.1× Citius Pharmaceuticals Inc's market cap, and ConocoPhillips pays a 2.59% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and Citius Pharmaceuticals Inc for 16 Days on average.
| COP | CTXR | |
|---|---|---|
Market Cap | $155.98B | $13.79M |
Volume | 4,774,951 | 156,684 |
Sector | Energy | Health |
52-Week High | $141.22 | $1.82 |
52-Week Low | $85.66 | $0.48 |
Typical Hold Time | 79 Days | 16 Days |
Enterprise Value | $171.58B | $3.96M |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $134.19, up 3.74% with strong technical momentum and bullish moving averages. The company shows solid fundamentals with Q2 2026 EPS beating expectations at $3.24 versus $2.90, supported by a 20-year LNG supply agreement with Venture Global announced October 1, 2026. Valuation metrics remain reasonable with P/E of 17.17 and EV/EBITDA of 6.17, while analyst consensus favors Buy ratings (75%) with a $154.75 price target.
Outlook remains positive given robust cash flow generation and strategic LNG expansion, though risks include oil price volatility and geopolitical exposure. The stock offers value with upside potential to analyst targets, but investors should monitor execution on international asset sales and energy market dynamics.
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
